|
Volumn 17, Issue 1, 2003, Pages 75-76
|
Letter to the editor
|
Author keywords
[No Author keywords available]
|
Indexed keywords
AMINOTRANSFERASE;
AZATHIOPRINE;
CYCLOSPORIN A;
HEPATITIS B ANTIBODY;
HEPATITIS B SURFACE ANTIGEN;
HEPATITIS C ANTIBODY;
HEPATITIS C ANTIGEN;
IMMUNOSUPPRESSIVE AGENT;
VIRUS ANTIBODY;
HEPATITIS B ANTIGEN;
AMINOTRANSFERASE BLOOD LEVEL;
CARDIOVASCULAR DISEASE;
CAUSE OF DEATH;
CONTROLLED STUDY;
GRAFT SURVIVAL;
HEMODIALYSIS PATIENT;
HEPATITIS B;
HEPATITIS B VIRUS;
HEPATITIS C;
HEPATITIS C VIRUS;
HUMAN;
KIDNEY DONOR;
KIDNEY GRAFT REJECTION;
KIDNEY TRANSPLANTATION;
LETTER;
LIVER FAILURE;
LIVER HISTOLOGY;
MAJOR CLINICAL STUDY;
MORBIDITY;
MORTALITY;
PRIORITY JOURNAL;
TREATMENT OUTCOME;
VIRUS HEPATITIS;
BLOOD;
GRAFT REJECTION;
NOTE;
RISK FACTOR;
SURVIVAL RATE;
VIROLOGY;
GRAFT REJECTION;
GRAFT SURVIVAL;
HEPATITIS B;
HEPATITIS B ANTIGENS;
HEPATITIS C;
HEPATITIS C ANTIBODIES;
HUMANS;
KIDNEY TRANSPLANTATION;
RISK FACTORS;
SURVIVAL RATE;
|
EID: 0038623008
PISSN: 09020063
EISSN: None
Source Type: Journal
DOI: 10.1034/j.1399-0012.2003.02077.x Document Type: Letter |
Times cited : (3)
|
References (4)
|